Fly News Breaks for October 9, 2015
AZN, CLVS
Oct 9, 2015 | 10:37 EDT
AstraZeneca (AZN) as temporarily stopped two cancer drug combination trials evaluating the combo of its pipeline drugs AZD9291, a key competitor to Cloviss Roci, as a result of reports of lung disease. Goldman views the news as an incremental positive for Clovis, as it possibly limits AstraZeneca's ability to combine '9291 with some other drugs. The firm rates Clovis shares a Conviction Buy with a $123 price target on shares.
News For CLVS;AZN From the Last 2 Days
AZN
Apr 25, 2024 | 05:52 EDT
Consensus $4.56. Backs FY24 revenue view up low double-digit to low teens percentage, consensus $50.95B. Sees FY24 core tax rate 18%-22%.